TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.

TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.

TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.

TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.

TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.

TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…

TS-049491 — Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that can be used for preclinical tumor immunology and cancer biology studies.

TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.

TS-041504 — Dr. Nicholas Denko and colleagues at The Ohio State University have developed papaverine derivatives that can be used as metabolic radiosensitizers in hypoxic tumors. The compounds make cancer cells more sensitive to radiation therapy without the concomitant toxicity issues that can occur as a side-effect of papaverine.

TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.

TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.

TS-039267 — A non-invasive and automated tumor budding image analysis system for colorectal cancer. This program can detect tumor buds in traditional H&E stained sections without the need for manual assessment.

TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.

TS-038384 — A novel device for monitoring cancer cell motility in real time using standard microscopy.

TS-038221 — A knock-in murine model that expresses high levels of GFP in CXCR3 positive cells.

TS-038065 — OSU­-SpARKFUSE is an RNA sequencing assay that detects known and novel gene fusion mutations in multiple cancer types.

TS-038027 — Novel dihdroorotate dehydrogenase (DHODH) small-molecule inhibitors for the treatment of Acute Myeloid Leukemia, Multiple Myeloma, & Graft vs. Host Disease / Leukemia.

TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.

TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.

TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.